Total buying$00 buys
TBPH
Theravance Biopharma, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$00 sells
Net open-market+$0Buying minus selling
Active insiders13Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Sep 28, 2026
Open-market transaction mix · 0 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (13)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- OD—
- MJ—
- GS—
- SL—
TBPH transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
TBPHTheravance Biopharma, Inc. | O'Connor DonalDIR | D · returnSEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnSEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Mitchell Dean JDIR | D · returnSEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnSEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Gray SusannahDIR | D · returnSEC filing ↗ | UnknownView disclosure → | |
TBPHTheravance Biopharma, Inc. | Smaldone Alsup LaurieDIR | D · returnDerivative securitySEC filing ↗ | UnknownView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period69transactionstxns
- D · Issuer dispositions · dominant68 · 99%
- J · Other1 · 1%
Activity by reported role
A joint filing can contribute to multiple rolesDirector50
SVP12
Chief executive officer6
Chief financial officer3
COMM3
DEV3
GC3
HIO3
MA3
SECY3
10% owner1
Reported Holdings After
Separated by insider, security, and ownership type
Smaldone Alsup LaurieShare Option (Right to Buy) · Direct
0Sep 23, 2026
Mitchell Dean JShare Option (Right to Buy) · Direct
0Sep 23, 2026
O'Connor DonalShare Option (Right to Buy) · Direct
0Sep 23, 2026
Pakianathan DeepikaShare Option (Right to Buy) · Direct
0Sep 23, 2026
Gray SusannahShare Option (Right to Buy) · Direct
0Sep 23, 2026
Grimaud Brett A.Ordinary Shares · Direct
0Sep 23, 2026
Sawaf AzizOrdinary Shares · Direct
0Sep 23, 2026
Winningham Rick EOrdinary Shares · Direct
0Sep 23, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Theravance Biopharma, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Theravance Biopharma, Inc.?
WAM GP LLC, WEISS ANDREW M, Weiss Asset Management LP, PAKIANATHAN DEEPIKA, O'Connor Donal, MITCHELL DEAN J, GRAY SUSANNAH, Smaldone Alsup Laurie, Winningham Rick E, Sawaf Aziz, Miller Aine, Grimaud Brett A..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.